{
    "nct_id": "NCT03659136",
    "official_title": "XENERAâ„¢1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease",
    "inclusion_criteria": "* Documented histologically confirmed breast cancer with ERand/ or PgR-positive and HER2-negative status\n* Locally advanced or metastatic breast cancer not deemed amenable to curative surgery or curative radiation therapy\n* Archival tumour sample available at the time of informed consent and provided to the central laboratory around the time of randomisation. Patients must provide a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample preferably taken at the time of presentation with recurrent or metastatic disease (provision of a biopsy sample taken from the bone is not acceptable).\n* Patients must satisfy the following criteria for prior therapy:\n\n  * Disease progression during treatment or within 12 months of completion of endocrine adjuvant therapy or\n  * Disease progression while on or within 1 month after the end of prior endocrine therapy for advanced/metastatic breast cancer (Note: the endocrine therapy does not have to be the treatment immediately prior to trial entry).\n* Patients must have\n\n  * At least one measurable non-visceral lesion according to RECIST version 1.1 in either lymph nodes, soft tissue, skin and/or\n  * At least one measurable non-visceral lesion according to RECIST version 1.1 as lytic or mixed (lytic + blastic) in bone and/or\n  * At least one non-measurable (lytic, mixed lytic + blastic, or blastic) bone lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.\n* Fasting glucose <8.9 mmol/L (<160 mg/dL) and HbA1c <8.0%\n* Adequate organ function\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with agents targeting the IGF pathway, AKT, or mTOR pathways\n* Prior treatment with exemestane (except adjuvant exemestane stopped >12 months prior to start of study treatment as long as the patient did not recur during or within 12 months after the end of adjuvant exemestane)\n* Evidence of visceral metastasis/es (i.e. liver, lung, peritoneal, pleural metastases, malignant pleural effusions, malignant peritoneal effusions) at screening. NOTE: Patients with a past history of visceral metastases are eligible if visceral metastases have completely resolved at least 3 months\n* History or evidence of metastatic disease to the brain\n* Leptomeningeal carcinomatosis\n* More than 1 prior line of chemotherapy for HR+ HER2- metastatic breast cancer\n* Radiotherapy within 4 weeks prior to the start of study treatment\n* Use of concomitant systemic sex hormone therapy\n* History or presence of cardiovascular abnormalities\n* Known pre-existing interstitial lung disease\n* Further exclusion criteria apply",
    "miscellaneous_criteria": ""
}